483 related articles for article (PubMed ID: 37148526)
21. Molnupiravir compared to nirmatrelvir/ritonavir for COVID-19 in high-risk patients with haematological malignancy in Europe. A matched-paired analysis from the EPICOVIDEHA registry.
Salmanton-García J; Marchesi F; Koehler P; Weinbergerová B; Čolović N; Falces-Romero I; Buquicchio C; Farina F; van Praet J; Biernat MM; Itri F; Prezioso L; Tascini C; Vena A; Romano A; Delia M; Dávila-Valls J; Martín-Pérez S; Lavilla-Rubira E; Adžić-Vukičević T; García-Bordallo D; López-García A; Criscuolo M; Petzer V; Fracchiolla NS; Espigado I; Sili U; Meers S; Erben N; Cattaneo C; Tragiannidis A; Gavriilaki E; Schönlein M; Mitrovic M; Pantic N; Merelli M; Labrador J; Hernández-Rivas JÁ; Glenthøj A; Fouquet G; Del Principe MI; Dargenio M; Calbacho M; Besson C; Kohn M; Gräfe S; Hersby DS; Arellano E; Çolak GM; Wolf D; Marchetti M; Nordlander A; Blennow O; Cordoba R; Mišković B; Mladenović M; Bavastro M; Limongelli A; Rahimli L; Pagano L; Cornely OA
Int J Antimicrob Agents; 2023 Oct; 62(4):106952. PubMed ID: 37582478
[TBL] [Abstract][Full Text] [Related]
22. Characteristics and outcomes of US Veterans at least 65 years of age at high risk of severe SARS-CoV-2 infection with or without receipt of oral antiviral agents.
Gentry CA; Nguyen P; Thind SK; Kurdgelashvili G; Williams RJ
J Infect; 2023 Mar; 86(3):248-255. PubMed ID: 36702309
[TBL] [Abstract][Full Text] [Related]
23. Efficacy of Licensed Monoclonal Antibodies and Antiviral Agents against the SARS-CoV-2 Omicron Sublineages BA.1 and BA.2.
Fiaschi L; Dragoni F; Schiaroli E; Bergna A; Rossetti B; Giammarino F; Biba C; Gidari A; Lai A; Nencioni C; Francisci D; Zazzi M; Vicenti I
Viruses; 2022 Jun; 14(7):. PubMed ID: 35891355
[TBL] [Abstract][Full Text] [Related]
24. Association of Molnupiravir and Nirmatrelvir-Ritonavir with reduced mortality and sepsis in hospitalized omicron patients: a territory-wide study.
Wai AK; Lee TT; Chan SC; Chan CY; Yip ET; Luk LY; Ho JW; So KW; Tsui OW; Lam ML; Lee SY; Yamamoto T; Tong CK; Wong MS; Wong EL; Rainer TH
Sci Rep; 2023 May; 13(1):7832. PubMed ID: 37188726
[TBL] [Abstract][Full Text] [Related]
25. Treatment Options for Patients With Mild-to-Moderate Coronavirus Disease 2019 in Korea.
Jeon J; Chin B
J Korean Med Sci; 2022 Dec; 37(48):e352. PubMed ID: 36513054
[TBL] [Abstract][Full Text] [Related]
26. Comparative effectiveness of nirmatrelvir/ritonavir versus sotrovimab and molnupiravir for preventing severe COVID-19 outcomes in non-hospitalised high-risk patients during Omicron waves: observational cohort study using the OpenSAFELY platform.
Zheng B; Tazare J; Nab L; Green AC; Curtis HJ; Mahalingasivam V; Herrett EL; Costello RE; Eggo RM; Speed V; Bacon SC; Bates C; Parry J; Cockburn J; Hester F; Harper S; Schaffer AL; Hulme WJ; Mehrkar A; Evans SJ; MacKenna B; Goldacre B; Douglas IJ; Tomlinson LA;
Lancet Reg Health Eur; 2023 Nov; 34():100741. PubMed ID: 37927438
[TBL] [Abstract][Full Text] [Related]
27. Real-world Effectiveness of Molnupiravir and Nirmatrelvir/Ritonavir as Treatments for COVID-19 in Patients at High Risk.
Paraskevis D; Gkova M; Mellou K; Gerolymatos G; Psalida N; Gkolfinopoulou K; Kostaki EG; Loukides S; Kotanidou A; Skoutelis A; Thiraios E; Saroglou G; Zografopoulos D; Filippou D; Mossialos E; Zaoutis T; Gaga M; Tsiodras S; Antoniadou A
J Infect Dis; 2023 Dec; 228(12):1667-1674. PubMed ID: 37565522
[TBL] [Abstract][Full Text] [Related]
28. Real-life comparison of mortality in patients with SARS-CoV-2 infection at risk for clinical progression treated with molnupiravir or nirmatrelvir plus ritonavir during the Omicron era in Italy: a nationwide, cohort study.
Torti C; Olimpieri PP; Bonfanti P; Tascini C; Celant S; Tacconi D; Nicastri E; Tacconelli E; Cacopardo B; Perrella A; Buccoliero GB; Parruti G; Bassetti M; Biagetti C; Giacometti A; Erne EM; Frontuto M; Lanzafame M; Summa V; Spagnoli A; Vestri A; Di Perri G; Russo P; Palù G
Lancet Reg Health Eur; 2023 Aug; 31():100684. PubMed ID: 37547273
[TBL] [Abstract][Full Text] [Related]
29. Efficacy and Safety of Nirmatrelvir/Ritonavir, Molnupiravir, and Remdesivir in a Real-World Cohort of Outpatients with COVID-19 at High Risk of Progression: The PISA Outpatient Clinic Experience.
Tiseo G; Barbieri C; Galfo V; Occhineri S; Matucci T; Almerigogna F; Kalo J; Sponga P; Cesaretti M; Marchetti G; Forniti A; Caroselli C; Ferranti S; Pogliaghi M; Polidori M; Fabiani S; Verdenelli S; Tagliaferri E; Riccardi N; Suardi LR; Carmignani C; Batini S; Puccetti L; Iapoce R; Menichetti F; Falcone M
Infect Dis Ther; 2023 Jan; 12(1):257-271. PubMed ID: 36441485
[TBL] [Abstract][Full Text] [Related]
30. Editorial: Current Status of Oral Antiviral Drug Treatments for SARS-CoV-2 Infection in Non-Hospitalized Patients.
Parums DV
Med Sci Monit; 2022 Jan; 28():e935952. PubMed ID: 34972812
[TBL] [Abstract][Full Text] [Related]
31. Successful treatment of persistent SARS-CoV-2 infection with nirmatrelvir/ritonavir plus sotrovimab in four immunocompromised patients.
Lanzafame M; Gottardi M; Guella L; Collini L; Costa G; Guella A; Vento S
J Chemother; 2023 Nov; 35(7):623-626. PubMed ID: 37102326
[TBL] [Abstract][Full Text] [Related]
32. Combination regimen of nirmatrelvir/ritonavir and molnupiravir for the treatment of persistent SARS-CoV-2 infection: A case report and a scoping review of the literature.
Marangoni D; Antonello RM; Coppi M; Palazzo M; Nassi L; Streva N; Povolo L; Malentacchi F; Zammarchi L; Rossolini GM; Vannucchi AM; Bartoloni A; Spinicci M
Int J Infect Dis; 2023 Aug; 133():53-56. PubMed ID: 37150351
[TBL] [Abstract][Full Text] [Related]
33. COVID-19 treatments approved in the European Union and clinical recommendations for the management of non-hospitalized and hospitalized patients.
Bellino S
Ann Med; 2022 Dec; 54(1):2856-2860. PubMed ID: 36259490
[TBL] [Abstract][Full Text] [Related]
34. Effectiveness of COVID-19 Treatment With Nirmatrelvir-Ritonavir or Molnupiravir Among U.S. Veterans: Target Trial Emulation Studies With One-Month and Six-Month Outcomes.
Bajema KL; Berry K; Streja E; Rajeevan N; Li Y; Mutalik P; Yan L; Cunningham F; Hynes DM; Rowneki M; Bohnert A; Boyko EJ; Iwashyna TJ; Maciejewski ML; Osborne TF; Viglianti EM; Aslan M; Huang GD; Ioannou GN
Ann Intern Med; 2023 Jun; 176(6):807-816. PubMed ID: 37276589
[TBL] [Abstract][Full Text] [Related]
35. Characteristics and Outcomes of US Veterans With Immunocompromised Conditions at High Risk of SARS-CoV-2 Infection With or Without Receipt of Oral Antiviral Agents.
Gentry CA; Nguyen PN; Thind SK; Kurdgelashvili G; Williams RJ
Clin Infect Dis; 2024 Feb; 78(2):330-337. PubMed ID: 37619991
[TBL] [Abstract][Full Text] [Related]
36. Dual combined antiviral treatment with remdesivir and nirmatrelvir/ritonavir in patients with impaired humoral immunity and persistent SARS-CoV-2 infection.
Pasquini Z; Toschi A; Casadei B; Pellegrini C; D'Abramo A; Vita S; Beccacece A; Bussini L; Chionsini MC; Dentale N; Cantiani A; Lazzarotto T; Bartoletti M; Nicastri E; Zinzani P; Giannella M; Viale P
Hematol Oncol; 2023 Dec; 41(5):904-911. PubMed ID: 37452579
[TBL] [Abstract][Full Text] [Related]
37. Nirmatrelvir or Molnupiravir Use and Severe Outcomes From Omicron Infections.
Lin DY; Abi Fadel F; Huang S; Milinovich AT; Sacha GL; Bartley P; Duggal A; Wang X
JAMA Netw Open; 2023 Sep; 6(9):e2335077. PubMed ID: 37733342
[TBL] [Abstract][Full Text] [Related]
38. The effect of nirmatrelvir-ritonavir on viral clearance and length of hospital stay in patients infected with SARS-CoV-2 omicron variants.
Wang Y; Zhao D; Chen X; Liu X; Xiao W; Feng L
Influenza Other Respir Viruses; 2023 Feb; 17(2):e13095. PubMed ID: 36843224
[TBL] [Abstract][Full Text] [Related]
39. Nirmatrelvir Plus Ritonavir for Early COVID-19 in a Large U.S. Health System : A Population-Based Cohort Study.
Dryden-Peterson S; Kim A; Kim AY; Caniglia EC; Lennes IT; Patel R; Gainer L; Dutton L; Donahue E; Gandhi RT; Baden LR; Woolley AE
Ann Intern Med; 2023 Jan; 176(1):77-84. PubMed ID: 36508742
[TBL] [Abstract][Full Text] [Related]
40. New Perspectives on Antimicrobial Agents: Molnupiravir and Nirmatrelvir/Ritonavir for Treatment of COVID-19.
Atmar RL; Finch N
Antimicrob Agents Chemother; 2022 Aug; 66(8):e0240421. PubMed ID: 35862759
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
